PubRank

Luanne M Metz

Author PubWeight™ 62.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 24.22
2 The promise of minocycline in neurology. Lancet Neurol 2004 2.06
3 Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002 2.00
4 IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004 1.61
5 Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002 1.52
6 Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 2005 1.22
7 Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci 2007 1.18
8 Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Can J Psychiatry 2005 1.10
9 Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 2005 1.09
10 Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008 1.09
11 Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004 1.08
12 Psychotic disorders in MS: population-based evidence of an association. Neurology 2005 1.06
13 Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol 2012 1.05
14 T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis. Neuroimage 2009 1.01
15 Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. Postgrad Med 2012 0.96
16 The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005 0.92
17 Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 2005 0.90
18 Environmental factors and their regulation of immunity in multiple sclerosis. J Neurol Sci 2012 0.90
19 Prevalence of multiple sclerosis in First Nations people of Alberta. Can J Neurol Sci 2007 0.90
20 Incidence of multiple sclerosis among First Nations people in Alberta, Canada. Neuroepidemiology 2006 0.89
21 Challenges in screening for depression in multiple sclerosis. Mult Scler 2010 0.88
22 The association of depression with disease course in multiple sclerosis. Neurology 2005 0.87
23 Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study. Mult Scler 2011 0.85
24 Major depressive disorder and health care costs in multiple sclerosis. Int J Psychiatry Med 2002 0.84
25 Posterior fossa lesion volume and slowed information processing in multiple sclerosis. Brain 2004 0.84
26 Descriptive epidemiology of affective disorders in multiple sclerosis. CNS Spectr 2005 0.84
27 Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003 0.84
28 Prolactin in multiple sclerosis. Mult Scler 2012 0.84
29 Adherence of adolescents to multiple sclerosis disease-modifying therapy. Pediatr Neurol 2009 0.84
30 The use of complementary and alternative therapies by people with multiple sclerosis. Chronic Dis Can 2003 0.83
31 Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J Neuroinflammation 2013 0.82
32 Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. CNS Neurosci Ther 2013 0.81
33 Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis. Trends Mol Med 2012 0.81
34 Clinical correlates of CES-D depressive symptom ratings in an MS population. Gen Hosp Psychiatry 2005 0.80
35 Foreign accent syndrome in a patient with multiple sclerosis. Can J Neurol Sci 2004 0.80
36 Disability in a community population with MS with and without mental disorders. Int J Psychiatry Med 2012 0.79
37 Affective disorders in motor neuron disease: a population-based study. Neuroepidemiology 2006 0.78
38 CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients. Mult Scler 2013 0.78
39 Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch Neurol 2010 0.78
40 Treatment trials in progressive MS--current challenges and future directions. Nat Rev Neurol 2013 0.77
41 Hopelessness ratings in relapsing-remitting and secondary progressive multiple sclerosis. Int J Psychiatry Med 2002 0.77
42 Sensory temporal thresholds and interhemispheric transfer times in multiple sclerosis: a preliminary study of a new outcome measure. J Clin Exp Neuropsychol 2003 0.76
43 Depression as a predictor of occupational transition in a multiple sclerosis cohort. Funct Neurol 2014 0.75
44 Health status, stress and life satisfaction in a community population with MS. Can J Neurol Sci 2012 0.75